News and Reports
-
Electra Therapeutics Announces $183 Million Series C Financing to Advance First-in-Class SIRP-Targeted Therapies for Immune Disorders and Cancer
22 October 2025Download -
Aculys Pharma Acquired by Viatris
16 October 2025Download -
Genmab to Acquire Merus Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model
29 September 2025Download -
Numab Therapeutics Achieves Milestone in Collaboration with Boehringer Ingelheim
25 September 2025Download -
89bio, Inc. Announces Agreement to be Acquired by Roche
18 September 2025Download -
Monte Rosa Therapeutics Anounces Colaboration with Novartis for Degraders to Treat Imune-mediated Diseases Degraders to Treat Immune-mediated Diseases
15 September 2025Download -
Fangzhou and Innovent Biologics Form Strategic Alliance for AI-Powered Weight Management Solutions
10 September 2025Download -
LUNDBECK SELECTS SWIXX AS A KEY PARTNER IN A TRANSFORMATIVE MULTI-REGIONAL DEAL
10 September 2025Download -
Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer
9 September 2025Download -
Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
2 September 2025Download -
IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed
11 August 2025Download -
Freenome Announces Exclusive License Agreement with Exact Sciences to Commercialize Freenome’s Blood-Based Screening Test for Colorectal Cancer
6 August 2025Download -
SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics
5 August 2025Download -
Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis
22 July 2025Download -
Fangzhou and Novo Nordisk Signed Collaboration Memorandum to Establish a New Ecosystem for Health Management
18 July 2025Download -
Neuron23 Announces $96.5 Million Series D Financing and First Patient Dosed in Global Phase 2 NEULARK Clinical Trial of NEU-411 for Early Parkinson’s Disease
25 June 2025Download -
Merus’ Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC
22 May 2025Download -
AbbVie and ADARx Pharmaceuticals Announce Collaboration and License Option Agreement to Develop Next-Generation siRNA Therapies Across Multiple Therapeutic Areas
14 May 2025Download -
Swixx and Biopas Expand Portfolio in Latin America, Securing 9 New Partnership Contracts in One Year
28 April 2025Download -
Aculys Pharma Signs 4.4 Billion Yen Series C Funding Round Agreement
24 March 2025Download -
VISEN Pharmaceuticals Announces the Offer Price and Allotment Results of the Global Offering
21 March 2025Download -
Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline
20 March 2025Download -
Curevo Raises $110 Million to Advance Amezosvatein Shingles Vaccine
17 March 2025Download -
Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension
10 March 2025Download -
NiKang Therapeutics® Announces First Patient Dosed in a Phase 1b/2 Study of NKT2152 in Combination with Standard-of-Care in First-Line Regimen for Hepatocellular Carcinoma
21 January 2025Download